BioAdaptives (BioAdaptives) ROCE % : 0.00% (As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is BioAdaptives ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. BioAdaptives's annualized ROCE % for the quarter that ended in Dec. 2023 was 0.00%.

BioAdaptives ROCE % Historical Data

The historical data trend for BioAdaptives's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioAdaptives ROCE % Chart

BioAdaptives Annual Data

Trend

Dec13

Dec14

Dec15

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

BioAdaptives Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial															-	-	-	-	-

BioAdaptives ROCE % Calculation

BioAdaptives's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-0.55	/	( ( (0.037 - 1.489)	+	(0.104 - 1.751) )	/ 2 )
	=	-0.55	/	( (-1.452	+	-1.647)	/ 2 )
	=	-0.55	/	-1.5495
	=	35.50 %

BioAdaptives's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	-0.916	/	( ( (0.329 - 1.475)	+	(0.104 - 1.751) )	/ 2 )
	=	-0.916	/	( ( -1.146	+	-1.647 )	/ 2 )
	=	-0.916	/	-1.3965
	=	0 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

BioAdaptives (OTCPK:BDPT) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

BioAdaptives ROCE % Related Terms

Thank you for viewing the detailed overview of BioAdaptives's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

BioAdaptives (BioAdaptives) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » BioAdaptives Inc (OTCPK:BDPT) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

2620 Regatta Drive, Suite 102, Las Vegas, NV, USA, 89128

Website

https://www.shopbioadaptives.com

BioAdaptives Inc is engaged in investigating, marketing and distributing natural plant- and algal-based products and medical devices that improve health and wellness for humans and animals, with an emphasis on pain relief, anti-viral function, and anti-aging properties. Its products include dietary supplements using natural ingredients and proprietary methods of optimizing the availability of nutrients in foods and beverages. The human products are designed to aid memory, cognition and focus; assist in sleep and fatigue reduction; provide pain relief and healing; and improve overall emotional and physical wellness. Its product lines include PluriPain, PrimiLungs, SleepEZ, MindNMemory, Cell Rejuven and ProteinNMore.

Executives

Richard Chiang	other: Previous Officer and Director	460 BRANNAN STREET SUITE 78064, SAN FRANCISCO CA 94107
Barry Epling	director	2251 NORTH RAMPART BLVD., #182, LAS VEGAS NV 89128
Ferris Holding Inc.	10 percent owner	2251 NORTH RAMPART BLVD., #182, LAS VEGAS NV 89128
Gerald Epling	director, officer: Pres, CEO, Secretary, CFO	2251 NORTH RAMPART BLVD., #182, LAS VEGAS NV 89128